

Research Article

Burden of Antibiotic Resistance at Wolaita Sodo University Comprehensive Specialized Hospital

Temesgen Anjulo Ageru,¹ Habtamu Seid,¹ Temesgen Lera Abiso,² Abera Kumalo³, Temesgen Sidamo,⁴ and Tamrat Balcha⁴

¹Department of Medical Laboratory Services, Wolaita Sodo University Comprehensive Specialized Hospital, Wolaita, P.O. Box 138, Ethiopia

²School of Public Health, College of Health Sciences and Medicine, Wolaita Sodo University, Wolaita, P.O. Box 138, Ethiopia
³School of Medical Laboratory, College of Health Sciences and Medicine, Wolaita Sodo University, Wolaita, P.O. Box 138, Ethiopia
⁴School of Pharmacy, College of Health Sciences and Medicine, Wolaita Sodo University, Wolaita, P.O. Box 138, Ethiopia

Correspondence should be addressed to Tamrat Balcha; tamrat.balcha@wsu.edu.et

Received 14 March 2022; Revised 29 April 2022; Accepted 24 May 2022; Published 1 June 2022

Academic Editor: Mohamed Salah Abbassi

Copyright © 2022 Temesgen Anjulo Ageru et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Antibiotic resistance is a serious threat to the human population everywhere. However, less attention is given to its concern in sub-Saharan Africa including Ethiopia. There is an information gap concerning antibiotic resistance and its pattern in Wolaita Sodo University Teaching Referral Hospital. This study is aimed at investigating the prevalence of antimicrobial resistance in the study area. *Methods.* Five-year retrospective data of cultures and records of 581 patients were utilized to analyze the pattern of antibiotic resistance. The statistical software including SPSS version 25 and Microsoft excel 2013 were used. Laboratory records with incompletely registered age, sex, culture isolation, or drug susceptibility test data were excluded. *Results.* Out of the total of 581 samples extracted from the microbiology laboratory, 237 (40.8%) samples were culture positive for bacteria. From positive culture growth, 165 (69.6%) were gram-positive bacteria whereas 72 (30.4%) were gram negative. *Staphylococcus aureus* was the most prevalent isolate among gram-positive isolates as *Escherichia coli* was for gram-negative bacteria was 58.8%.*Conclusion. S. aureus* and *E. coli* were found to be the most prevalent pathogenic isolates among gram-positive and gram-negative bacteria, respectively. Most of the isolated pathogens showed high resistance towards the commonly prescribed antibiotic agents. The overall antibiotic resistance in this study was 57.7%, and the overall MDR prevalence was 72.2%.

1. Introduction

Antimicrobial resistance (AMR) is one of the major crises of public health and is among the most serious intimidations of the world. This is because it despairs the opportunity of treating morbidities caused by parasites, viruses, fungi, and bacteria [1]. Without any discrimination with respect to economy, age, gender, and/or race [2, 3], it is an eventual ability of these pathogens to resist to the prescribed medicines, the antimicrobials [1, 4, 5]. Many mechanisms can contribute to the resistance: acquisition of resistant genes or mutation in genes that encode for proteins involved, enzymatic hydrolysis, changes in cell membrane response, and/or impermeability [5–7]. Although it may happen naturally, misuse of antibiotics in humans and animals is the leading cause of AMR [4]. The AMR makes the antimicrobials ineffective against the microbial diseases [4, 5]. Multidrugresistant (MDR) bacteria are bacteria that are nonsusceptible to one or more antibiotic agents in three or more antimicrobial categories whereas "extensive" or "extremely" drug-resistant (XDR) bacteria are those that are nonsusceptible to one or more antibiotic agents in all but two or less antimicrobial classes. When bacteria are nonsusceptible to all antimicrobial agents listed, the bacteria are considered as "pan drugresistant" (PDR) [8]. The over consumption of antibiotics in general medicine, veterinary, or agriculture has led to a spike

in drug-resistant microorganisms [9]. MDR and XDR bacteria have become a major public health threat, and their prevalence in hospital settings is alarmingly increasing [10]. Multiantibiotic-resistant bacteria acquire resistance by mutation and gene transfer via conjunctions, transformation, or transduction [5]. The spread of MDR bacteria from one person to another most often occurs when someone who is colonized with a resistant organism but not ill transmits it to another who then also becomes colonized [10]. The out of pocket money for treating resistant infections is significantly higher than that for nonresistant infections because of longer duration of illness, additional tests, and the need for more expensive medicines [2]. The catastrophe impedes or interferes with the ability to treat infections. It also exerts extremely costly implications cascading to global health, food sustainability, security, environmental wellbeing, product development costs, market failure, and socioeconomic development [11, 12]. Most of its impacts fall on low- and middle-income countries owing to lack of infrastructure and human and financial resources to adequately prevent the drug resistance [12]. The other reasons are high prevalence of infectious diseases, shortage of trained health professionals, irrational use of drugs, and limited microbiological laboratory establishments [2, 3]. In addition, the consequences of AMR are aggravated in situations such as civil unrest, violence, famine, and natural disasters as well as in settings with poor health care services because these situations impair the political momentum of combating AMR [11, 13]. According to WHO report of 2014, in five out of six WHO regions, Escherichia coli resistance to third generation cephalosporins and fluoroquinolones and that of Staphylococcus aureus to methicillin are higher than 50%. The report claims 45% of deaths in both Africa and South-East Asia were because of multiantibiotic-resistant bacteria. It further reveals that third generation cephalosporin-resistant K. pneumonia was cause of high mortality in Africa (77%), Eastern Mediterranean region (50%), South East Asia (81%), and Western Pacific region (72%) [3]. Literature reveals that the rate of AMR varies from region to region and hospital to hospital [14]. Wolaita Sodo University Comprehensive Specialized Hospital is a government hospital that provides general outpatient and inpatient services including medical, surgical, pediatric, psychiatric, ophthalmic, gynecological, and obstetric emergency cares. Annual patient volume is around 200,000. There is no evidence of published work in the literature regarding the burden of antibiotic resistance at this hospital. The current study is aimed at retrospectively investigating the antibiotic resistance pattern of bacteria isolated from different specimens to the commonly prescribed antibiotics at the hospital.

2. Materials and Methods

2.1. Materials. MacConkey agar, blood agar, urea agar, and chocolate agar manufactured by Sisco Research Laboratories Ltd (India); trypticase Soy broth, Thayer Martin agar, and oxidase manufactured by Oxoid Ltd (UK); lysine iron agar and mannitol salt agar manufactured by Biomark Laboratories Ltd (India); Simmons Citrate Agar and indole manufactured by Himedia Laboratories Ltd (India); catalase (hydrogen peroxide manufactured by Wasse Pharma, Ethiopia); bile esculin agar manufactured by Merck[®] (Germany); and coagulase manufactured by NVI (Debrezeit, Ethiopia) were the materials used for different purposes and stages of the present study. All the antibiotic discs used including bacitracin (BAC 10 μ g), optochin (OPT 5 μ g), novobiocin (NOV 30 μ g), ampicillin (AM 10 μ g), gentamicin (GM 10 μ g), cloxacillin (CXC 5 μ g), ciprofloxacin (CIP 5 μ g), ceftriaxone (CRO 30 μ g), nalidixic acid (NA 30 μ g), ceftazidime (CAZ 30 μ g), cephalexin (CN 30 μ g), amoxicillin/clavulanic acid (AMC 20/10 μ g), trimetho-prim/sulfamethoxazole (SXT 1.25/23.75 μ g), chloramphenicol (C 30 μ g), tetracycline (TE 30 μ g), clindamycin (CM 2 μ g), erythromycin (E 15 μ g), and vancomycin (VA 30 μ g) were manufactured by Abtek Ltd (UK).

2.2. Methods

2.2.1. Study Setting and Design. The study was conducted at Wolaita Sodo University Comprehensive Specialized Hospital (WSUTRH) located 329 km to the south of Addis Ababa, capital of Ethiopia. The institution-based five-year (2016-2020) retrospective design was used. Data were collected from June 20/2019 to July 20/2019 and August 1-28 2021. The source population was comprised of all patients who had attended the hospital during 2016-2020, and the study population was all the patients for whom culture had been required and performed during the study period.

2.2.2. Inclusion and Exclusion Criteria. All the encounters' results with complete data registered in the logbook during the study period were included, and all the encounters' results with incomplete data were excluded.

2.2.3. Data Collection. Demographic data of patients pro and files of the bacteria isolated including susceptibility status were retrieved from the microbiology laboratory register books using a standard data collection form. The types of samples which had been collected include urine, stool, body fluid, blood, and pus. These samples had been inoculated accordingly in the culture media and incubated at 37°C based on standard operating procedures, and the growth had been observed after 16-24 hrs.

2.2.4. Microbiological Isolation and Identification. In case blood stream infection was suspected, blood culture media trypticase Soy broth was prepared and blood sample was inoculated aseptically. The samples with hemolysis, gas, and turbidity were subcultured on appropriate media for further isolation. MacConkey and blood agar media were utilized to isolate nonfastidious bacteria whereas chocolate agar media were applied to culture fastidious bacteria. For the samples collected from genital area, Thayer Martin agar media were used. In case growth was observed, a colony from culture was selected and gram stained. Biochemical tests were selected based on their gram reaction. Gramnegative bacteria were further identified using oxidase, citrate, urease, lysine iron agar, mannitol, and indole tests. Gram-positive bacteria were identified using catalase, coagulase, bacitracin, optochin, bile solubility, and novobiocin. By using gram staining, identification of some bacteria was

performed up to species level for some and genus level for the others.

2.2.5. Antibiotic Resistance Testing. Antibiotic resistance test was conducted, and interpretation was performed based on the standard Kirby-Bauer disc diffusion method of Clinical Laboratories Standard Institute (CLSI) 2014–2017. The test results were reported based on whether the isolates were resistant towards recommended doses of the antibiotics for the site of infection. The "resistant" category implied that isolates were not inhibited by the usually achievable concentrations of the agent with normal dosage schedules. Another implication of "resistant" category was demonstration of minimum inhibitory concentration (MIC) or zone diameters that fall in the range where specific microbial resistant mechanisms are likely, and clinical efficacy of the agent against the isolate was not reliably shown in treatment studies.

2.2.6. Quality Assurance. Before testing all the inoculated samples, a standard bacteriological procedure was followed to maintain correct laboratory test results. American Type Culture Collection (ATCC) standard reference strains of *Escherichia coli* (ATCC-25922), *Staphylococcus aureus* (ATCC 25923), and *Pseudomonas aeruginosa* (ATCC-25853) were used to control the quality of the culture and drug susceptibility testing. All data were checked for consistency and completeness.

2.2.7. Ethical Considerations. The ethical clearance was obtained from the ethical review committee of Wolaita Sodo University, College of Health Science and Medicine. Formal consent was also obtained from Wolaita Sodo University Referral Hospital. For privacy reason, all data was kept confidential. Anonymity of records was maintained by using registration number and unique code numbers used by service providers at Wolaita Sodo University Comprehensive Specialized Hospital.

2.2.8. Data Processing and Analysis. The data were cleaned and analyzed by using SPSS Version 25 and Microsoft excel 2013 software. The results were summarized using descriptive presentations like frequency and percent distributions when appropriate [15].

3. Results and Discussions

3.1. Sociodemographic Characteristics of the Subjects. Out of total of 581 encounters, males were 304 (52.3%) and 277 (47.7%) were females. From the total of 581 patients, 166 (28.6%), 124 (21.3%), and 117 (20.1%) visited the microbiological laboratory in the year 2020, 2017, and 2016, respectively (Figure 1(a)). The majority of the age groups, 126 (21.7%), were below five years, and the age group least in number was 45 years and older, 62 (10.7%) (Figure 1(b)). Similarly, the majority, 47.2%, of specimens used for culturing were body discharges and pus (Figure 2). This comparative distribution was in agreement with a report from Yemen [16].

3.2. Growth of Isolates. Out of the total specimens inoculated, 237 (40.8%) showed positive bacterial growth whereas 344 (59.2%) did not show any growth (Figure 2(b)). This was significantly lower than the rate of growth reported from Gondar, 70.2%. The reason for the lower rate might be inefficient screening of the specimens [17]. Distribution of growth status of bacteria in the different age groups is shown in Figure 3. The age group with highest number of growth, 55, was 15-24 years which contributed 23.2% of the total growth. The rate of bacterial growth for this group was 48.7% which indicates the highest efficiency of screening of encounters for culture. In contrast, the age group with least number of growth, 29, was ≥44 years which contributed 12.2% of the total growth. The rate of bacterial growth in the specimens from the oldest group was 46.8% which could be taken as the second highest efficiency of screening of encounters for culture. The least efficiency of screening of the encounters for the culture, 34.2%, was observed in the age group 25-34 years.

Concerning the sources of specimens used for bacterial isolation, 274 (47.2%) were discharges from vagina, urethra, and wound; 71 (12.2%) were from stool; 108 (18.6%) were from urine, 125 (21.5%) were from body fluids, and 3 (0.5%) were from others (Figure 2(b)). The top three bacteria isolated from the positive growths in this study were S. aureus 132 (55.7%), E. coli 30 (5.2%), and P. aurogenous 27 (4.6%). That S. aureus and E. coli were successively the most prevalent isolates was consistent with studies reported elsewhere in Ethiopia [2, 18]. Among those 237 positive growths, based on their gram reaction, 165 (69.6%) were gram positive and 72 (30.4%) were gram negative. This was in contrast to the studies conducted elsewhere where the rate of growth was higher for gram-negative isolates than the gram-positive ones [19, 20]. The reason might be the higher proportion specimens pertaining to body discharges and pus which are the most common sites of S. aureus manifestations [21] and/or variation of bacterial etiology across geographical conditions. Gram-positive bacteria identified were S. aureus, S. pyogenes, S. pneumonia, and S. saprophytes whereas gram-negative bacteria isolated include E. coli, P. aurogenous, Proteus species, Salmonella species, Shigella species, and Neisseria species (Table 1). Differences in species prevalence rates might happen by virtue of differences in places of specimen collection or their distribution in the various environments.

3.3. The Antibiotic Resistance of Bacterial Isolates. The resistance of gram-positive bacteria to the tested antibiotics is shown in Table 2. Its values ranged from 55.7% of S. aureus to 64.6% of S. saprophytes, and its average value was 57.2% whereas the overall resistance in this study was 57.7%. This value was lower than that conducted in Debre Markos Referral Hospital, Ethiopia, 84.6% for gram-positive bacteria [22–24] which might be due to some updates in microbiological set-ups and better awareness of prescribers [25]. The most prevalent isolate among all the bacterial growths in this study was *S. aureus*, 132 (55.7%), which is consistent with the findings from the study conducted in Gabon, Central Africa [2]. It was resistant to many of the antibiotics



FIGURE 1: (a) Year of testing and (b) age group of patients involved in antibiotic resistance study at WSUCSH, 2016-2020.



FIGURE 2: (a) Types and the (b) overall growth rate in the specimens inoculated for antibiotic resistance study at WSUCSH, 2016-2020.



FIGURE 3: Distribution of growth of bacterial isolates among different age groups from which the specimens were collected.

tested including ampicillin, tetracycline, vancomycin, and chloramphenicol. In this regards, the findings agree to the findings reported from elsewhere [18, 20, 26]. Its resistance to the tested antibiotics ranged from 15 to 86% with the overall rate of 55.7% which is lower than the report from Greek where it was 88% [27]. On the other hand, it was higher than the report of resistance, 40%, observed in patients with suspected peritonitis in Southern Ethiopia [28] and the 3 years retrospective study report from the same region in which the resistance of *S. aureus* was 42.02% [23] to the respective antibiotics. Its resistance was highest to ampicillin (86.0%), 74.2% to vancomycin, 66.1% to ceftriaxone, 55.7% to cephalexin, 68.8% to cloxacillin, 73.4% to chloramphenicol, and 48.3% to erythromycin. The resistance of gram-positive bacterial isolates was highest to ampicillin and tetracycline which is in line with studies

TABLE 1: Types and distribution of isolated bacteria at WSUTRH,2016-2018.

Bacteria		Frequency	Percentage (%)
	S. aureus	132	55.7
	S. pyogenes	12	5.1
Gram-positive	S. pneumonia	7	3.0
bacteria	S. saprophytes	14	5.9
	Subtotal	165	69.6
	P. aurogenous	27	11.4
	E. coli	30	12.7
	Proteus spp.	5	2.1
Gram-negative	Shigella	5	2.1
bacteria	Neisseria spp.	3	1.3
	Salmonella	2	0.8
	Subtotal	72	30.4
	Total	237	100%

conducted elsewhere in Ethiopia and Nigeria [20, 29]. The resistance towards ampicillin in this study was extremely higher than that reported for Enterococci elsewhere in Ethiopia [30]. The overall resistance towards ampicillin was lower than the reports from elsewhere [31, 32] but significantly higher than the other reports [16]. The reason for high resistance towards ampicillin and also others might be due to overuse of these antibiotics [33]. The overall resistance of S. pyogenes and S. pneumonia were found to be 58.8% and 62.8%, respectively. The highest resistance of S. pyogenes was observed for ceftriaxone. The probable reason for this finding might be extreme and nonprioritized overuse of ceftriaxone. The lowest resistance of S. pyogenes was observed for ciprofloxacin and erythromycin. The overall resistance of tested gram-positive bacteria was 82.2% to ampicillin, 75.6% to tetracycline, 73.7% to chloramphenicol, and 73.5% to gentamicin. The resistance of erythromycin was similar to the findings from elsewhere [34]. The overall resistance of the bacterial isolates towards vancomycin was 72.2% which was in line with the report that vancomycin resistance is rising in Ethiopia [30]. The reason for vancomycin resistance had been scrutinized to be availability of encoding system for the synthesis of low affinity precursors and elimination of high affinity precursors [35]. It notifies a great threat to the public health because vancomycin is the medicine reserved for seriously ill patients or for penicillin, cephalosporin, and other antibiotic-resistant infections [36].

The antibiotic resistance of gram-negative bacteria isolated towards commonly prescribed antibiotics is shown in Table 3. The overall resistance of gram-negative bacteria in this study (58.8%) was lower than that reported from southern Ethiopia University Teaching Hospitals, 84.0% [23]. The least resistance of the gram-negative bacterial isolates, 55.6%, was observed for *Salmonella* which was comparable to that of *E. coli*, 55.8%. In contrast, the highest

resistance was that of E. proteus, 63.2%, which was slightly more resistant than N. meningitis (60.0%). The overall resistance of E. coli ranged from 19% of nalidixic acid to that of tetracycline, 89%. Its overall resistance was 55.8%, and in the meta-analysis conducted in Ethiopia, it was 45.38% (33.5%-57.7%), the highest resistance in Addis Ababa and the least in the Tigray Region [37]. The specific rate of resistance of E. coli to cotrimoxazole was 80.0%, ceftriaxone was 70%, chloramphenicol was 50.0%, and gentamycin was 61.1%. Its resistance was relatively lowest, 18.8%, to nalidixic acid. The findings of this study could be taken as comparable to the previous studies conducted in Ethiopia and Egypt [23, 38, 39]. The overall resistance (56.7%) of gram-negative isolates to ceftriaxone was also lower than that reported from the study in Rewand Referral Hospital where out of 241 gram-negative isolates tested for ceftriaxone, 75.9% had been resistant [40]. The resistance of Salmonella species towards the overall antibiotics tested was 55.6% which was comparable with 54.55% which was the resistance of the same species reported from elsewhere in Ethiopia [31]. In contrast, it was lower than the report from Bangladesh, 62.94% [41]. The reason for this difference might be better prescribing and using practice of antibiotics, geographical variation, or the effect of sample size. The overall resistances of *P. aeruginosa* and Shigella species were revealed to be 63.9% and 61.1%, respectively. P. aeruginosa isolates were resistant to tetracycline (91.7%), ampicillin (66.7), and cotrimoxazole (60.0%). Comparable findings were also reported elsewhere from Ethiopia [28, 41, 42]. In addition, that it had lower resistance to ciprofloxacin was in line with the literature evidences [26, 43]. However, according to the present study, P. aeruginosa was resistant to gentamycin and ceftriaxone too and the prevalence of its overall resistance is rising.

Overall, most of the isolates including both grampositive and gram-negative bacteria were found to be resistant to the majority of the antibiotics. The same findings were reported in the literature elsewhere from Ethiopia [44, 45]. The average resistance of all the tested bacteria against ampicillin was 80.8% which was significantly higher than that reported elsewhere [16]. The reason might be overuse of the medicine. Upon analysis of the individual bacteria for resistance, S. saphropytic, S. pneumonia, P. aurogenous, Salmonella, Shigella, and E. proteus relatively had a larger overall proportion of resistance to the antibiotics. This finding is in agreement with a study reported from Hawassa where antibiotic resistance of gram-negative bacteria was higher than that of the gram-positive bacteria [23]. Ampicillin, tetracycline, chloramphenicol, and gentamicin were the first five successive antibiotics to which the highest grampositive bacteria resistance was observed. Similarly, tetracycline, ampicillin, cloxacillin, and cotrimoxazole were the antibiotics to which the highest record of gram-negative bacteria resistance was observed successively in decreasing order. The resistance rate to some antibiotics in this study was much higher than a recent study from other parts of Ethiopia. For instance, the resistance to penicillins and tetracyclines was in the range of 35-47% and 38-52% in grampositive bacteria, respectively. Also, the resistance rate of gram-positive bacteria to ceftriaxone was very lower (20%),

A (11 · () A 1	S. aur	S. aureus		genes	S. saphr	opytic	S. pneu	T (1 (0())	
Antibiotic tested	R/T	%R	R/T	%R	R/T	%R	R/T	%R	1 otal (%)
AM	49/57	86.0	5/8	62.5	4/5	80.0	2/3	67	60 (82.2)
С	58/79	73.4	4/7	57.1	7/9	77.8	4/4	100	73 (73.7)
GM	52/78	66.7	8/10	80.0	8/9	88.9	4/5	80	72 (73.5)
CXC	55/80	68.8	8/9	88.9	8/11	72.7	3/4	75	74 (71.2)
CRO	72/109	66.1	10/11	90.9	11/14	78.6	4/6	67	97 (69.3)
CIP	18/121	14.9	1/11	9.1	5/14	36	0/7	0	24 (15.7)
CL	31/105	29.5	4/9	44.4	4/13	31	3/6	50	42 (31.6)
SXT	19/31	61.3	4/6	66.7	6/7	86	2/3	67	31 (66.0)
TE	22/29	75.9	3/5	60.0	4/5	80	2/2	100	31 (75.6)
E	28/58	48.3	1/7	14.3	6/8	75	1/2	50	36 (48.0)
CN	34/61	55.7	5/6	83.3	4/8	50	1/3	33	44 (56.4)
VA	49/66	74.2	4/8	50.0	6/10	60	6/6	100	65 (72.2)
Overall	487/874	55.7	57/97	58.8	73/113	64.6	32/51	62.8	649 (57.2)

TABLE 2: The antibiotic resistance of gram-positive bacterial isolates.

AM: ampicillin; C: chloramphenicol; GM: gentamycin; CXC: cloxacillin; CTO: ceftriaxone; CIP: ciprofloxacin; CL: clindamycin; SXT: trimethoprim/ sulfamethoxazole; TE: tetracycline; E: erythromycin; CN: cefalexin; VA: vancomycin; R: resistant; T: number of tests conducted; %R: percent *resistance*.

A	Е. со	E. coli		P. aurogenous		Salmonella		Shigella		Proteus		ningitis	$T_{2} + 1 (0/)$
Antibiotic tested	R/T	%R	R/T	%R	R/T	%R	R/T	%R	R/T	%R	R/T	%R	1 otal (%)
AM	9/11	81.8	8/12	66.7	1/1	100.0	2/2	100.0	3/4	75.0	1/1	100.0	24 (77.4)
С	11/22	50.0	8/14	57.1	1/1	100.0	1/2	50.0	3/5	60.0	0/2	0	22 (47.8)
GM	11/18	61.1	11/18	61.1	1/2	50.0	1/2	50.0	2/5	40.0	1/3	33.3	27 (56.3)
CXC	8/14	57.1	16/19	84.2	-	-	1/1	100.0	2/2	100.0	-	-	27 (75.0)
CRO	16/23	69.6	22/26	84.6	-	-	1/5	20.0	3/4	75.0	2/2	100.3	34 (56.7)
NA	3/16	18.8	8/20	40.0	0/1	0	1/2	50.0	2/3	66.7	-	-	14 (33.3)
CPR	8/25	32.0	9/26	34.6	-	-	2/5	40.0	2/5	40.0	2/3	66.7	23 (36.0)
СМ	13/19	68.4	14/22	63.6	1/1	100.0	3/3	100.0	2/3	66.7	0/1	0	33 (67.3)
SXT	12/15	80.0	9/15	60.0	-	-	2/3	66.7	1/1	100.0	1/1	100.0	25 (71.4)
TET	8/9	88.9	11/12	91.7	1/1	100.0	3/3	100.0	3/3	100.0	1/1	100.0	27 (93.1)
ERY	5/13	38.5	8/16	50.0	0/1	0	0/1	0	1/2	50.0	1/1	100.0	15 (44.1)
CN	7/14	50.0	4/10	40.0	0/1	0	1/2	50.0	0/1	0	-	-	12 (42.9)
Overall	111/199	55.8	128/210	61.0	5/9	55.6	18/31	58.1	24/38	63.2	9/15	60.0	295 (58.8)

TABLE 3: The antibiotic resistance of gram-negative bacterial isolates.

AM: ampicillin; C: chloramphenicol; GM: gentamycin; CXC: cloxacillin; CRO: ceftriaxone; NA: nalidixic acid; CIP: ciprofloxacin; CM: clindamycin; SXT: trimethoprim/sulfamethoxazole; TE: tetracycline; E: erythromycin; CN: cefalexin; R: resistant; T: number of tests conducted; %R; percent resistance.

compared to the present study (69%). However, interestingly, the resistance rate to fluoroquinolones was lowest in both bacteria groups, and the resistance rate of gramnegative bacteria to penicillin's and ceftriaxone was comparable in both settings [46]. On the other hand, the resistance reported from the present study is higher than that reported by the studies conducted in the African countries which revealed antibiotic resistance of 34.6% in Benin, 31.9% in Congo, 14.3% in Togo, and 16.3%in Madagascar [47]. The overall resistance in the present study (57.7%) was lower than that reported from Central Ethiopia (72.2%) and also Debre Markos Referral Hospital, Ethiopia, 72.2% [22, 24, 48]. This could be due to some updates in diagnostic setups and better awareness of prescribers on rational prescribing [25]. It might also be because of differences in the geographical area, type of organisms, and the methods used.

3.4. Multidrug Resistance (MDR). The overall prevalence of MDR as per the present study was 72.2% which was significantly higher than that of Tigray (51.1%) and Amhara (68.6%). It was slightly higher than that of pooled MDR of the overall Ethiopia (70.5%) and the report of Oromia Region (70.1%). Still it was comparable to that of Addis Ababa (72.4%) but slightly lower than that of Harari (74.6%) and significantly lower than that of Sidama (81.7%). The differences in the MDR prevalence might be due to the differences in geography, client types, the types of bacteria, the methods used, and variations in the level of

implementation of infection prevention protocols [49]. The findings showed the MDR prevalence in the present study was higher than the report from elsewhere in Ethiopia, 47.8% [23]. The mean prevalence of MDR in gram-positive and gram-negative bacteria in the present study was 73.9% and 68.1, respectively. This shows the prevalence of MDR among the gram-positive bacterial isolates in this study was higher than the report from Bangladesh where it was 68.8% [50]. As indicated in Table 4, the gram-positive bacteria including S. saprophyte, S. pneumonia, and S. pyogenes experienced the highest MDR levels (100%) successively followed by P. aeruginosa (88.9%) and S. aureus (67.4%). Likewise, the prevalence of MDR in gram-negative bacteria was higher than the report of pooled MDR from elsewhere, 27% [51]. The MDR of each of E. coli and Salmonellae was 50% which was the lowest finding in the present study. This shows that the MDR of E. coli was lower than the report from Nigeria where its value was 88%. In addition, the Proteus species showed higher MDR in this study than that of the same study in Nigeria, 60% [52]. The reasons for the differences might be the differences in the types of bacteria tested, geographical conditions, profiles of patients, and practice of rational use of medicines. In general, the implication was that, in the study area, the effectiveness of treatment of bacterial infections with the commonly prescribed antibiotics could have been significantly affected by nonsusceptibility. In this regards, the antibiotic resistance has already become a great challenge in the study area requires further investigations and intervention.

4. Limitation of the Study

Since it is a retrospective study, detailed sociodemographic information and clinical status of patients were not incorporated. The number of drugs tested on some pathogens was small which could probably affect the representativeness. The total number of encounters was also less than optimum that it could probably have affected the findings. That the correlation of Kirby-Bauer zone of inhibition data with the minimum inhibitory concentration experimental data might also be taken as a limitation.

5. Conclusions and Recommendations

According to the present study, the most frequent bacterial isolates were S. aureus, E. coli, P. aurogenous, S. saprophytes, and S. pyogenes, in decreasing order. The commonly prescribed antibiotics would have questionable effectiveness for claimed therapeutic indications in the study area. The overall antibiotic resistance in this study was 57.7%. Its prevalence in gram-positive bacteria ranged from 55.7% of S. aureus to 64.6% of S. saprophytes, and its average value was 57.2%. The overall prevalence of MDR as per the present study was 72.2%. The MDR prevalence in the study area was higher than many reports from elsewhere in Ethiopia. The mean prevalence of MDR in gram-positive and gram-negative bacteria in the present study was 73.9% and 68.1, respectively. In this regards, the antibiotic resistance has been posing and will continue to pretense even more challenges to the public health in the study area unless proportional interventions are considered. In order to reveal impact and routes of antibiotic resistance, further studies including resistant gene identification should be conducted. The reasonable recommendations would comprise enthusiastic implementation of infection control protocols and antibiotic stewardship augmented with interdisciplinary collaboration of health care providers.

Abbreviations

AMR:	Antimicrobial resistance
ATCC:	American Type Culture Collection
MDR:	Multidrug resistance
MIC:	Minimum inhibitory concentration
SNNPR:	South Nations, Nationalities, and Peoples
	Region

TABLE 4: Multiple antibiotic resistance patterns of bacterial isolates in WSUCSH, 2016–2020.

R_0		R_0	R_1		R_2			R ₃		R_4		$R_5 \geq$		Total		MDR	
Bacteria	N	%	N	%	N	- %	N	%	N	%	N	%	N	%	N	%	
S. aureus	6	4.5	10	7.6	27	20.5	24	18.2	21	15.9	44	33.3	132	100	89	67.4	
S. saprophyte	0	0.0	0	0.0	0	0.0	4	28.6	2	14.3	8	57.1	14	100	14	100.0	
S. pneumonia	0	0.0	0	0.0	0	0.0	3	42.9	2	28,6	2	28.6	7	100	7	100.0	
S. pyogenes	0	0.0	0	0.0	0	0.0	5	41.7	2	16.7	5	41.7	12	100	12	100.0	
Subtotal	6	4.5	10	7.5	27	16.4	36	21.8	27	16.4	59	35.8	165	100	122	73.9	
P. aeruginosa	0	0.0	1	3.7	2	7.4	8	29.6	9	33.3	7	25.9	27	100	24	88.9	
E. coli	2	6.7	3	10	10	33.3	3	10.0	3	10.0	9	30.0	30	100	15	50.0	
Proteus spp.	0	0.0	0	0.0	2	40	0	0	0	0.0	3	60.0	5	100	3	60.0	
Shigella	0	0.0	1	20.0	0	0.0	1	20.0	2	40.0	1	20.0	5	100	4	80.0	
Salmonella	0	0.0	0	0.0	1	50.0	1	50.0	0	0.0	0	0.0	2	100	1	50.0	
N. meningitis	0	0.0	0	0.0	1	33.3	1	33.3	0	0.0	1	33.3	3	100	2	66.7	
Subtotal	2	2.8	5	6.9	16	22.2	14	19.4	14	19.4	21	29.2	72	100	49	68.1	
Total	8	34	15	63	43	181	50	21.1	41	173	80	33.8	237	100	171	72.2	

spp.:	Species
WHO:	World Health Organizations
WSUTRH:	Wolaita Sodo University Teaching Referral
	Hospital.

Data Availability

The authors confirm that all the data associated with this paper are available upon request.

Ethical Approval

The ethical clearance was obtained from the Ethical review committee of Wolaita Sodo University, College of Health Science and medicine. Formal permission was also obtained from Wolaita Sodo University Referral Hospital. For reasons of privacy, all data were kept confidential. Anonymity of records was maintained by using registration number and unique code numbers used by service providers at Wolaita Sodo University teaching referral hospital.

Disclosure

Although an earlier version of this article had been submitted to some other journal, since the manuscript needed significant further changes and data, the initiated publication process was terminated before incorporation of further data points of two more years and improvements on the manuscript including data analysis have been made. At the time, the Research Square had been allowed to present the preprint. The publication of this manuscript is not under consideration anywhere different from "BioMed Research International of Hindawi." Regarding the Research Square, the article was not submitted to it for publication but for simple presentation as unpublished content. Therefore, the authors ensure that there is no issue that could halt the consideration of this manuscript for publication in "BioMed Research International" journal of Hindawi [53].

Conflicts of Interest

The authors declare no conflict of interest.

Authors' Contributions

All the authors equally contributed to this research work.

Acknowledgments

The authors would like to appreciate Wolaita Sodo University, College of Health Sciences and Medicine.

References

- [1] WHO, Report on Surveillance of Antibiotic Consumption 2016-2018: Early Implementation, WHO, Geneva, Swizerland, 2018.
- [2] A. S. Alabi, L. Frielinghaus, H. Kaba et al., "Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa," *BMC Infectious Diseases*, vol. 13, no. 1, p. 455, 2013.

- [3] WHO, Antimicrobial Resistance: Global Report on Surveillance, WHO, Geneva, 2014.
- [4] WHO, *Global Action Plan on Antimicrobial Resistance*, WHO, Geneba, 2015.
- [5] F. Moges, M. Edris, A. Mulu et al., "The growing challenges of antibacterial drug resistance in Ethiopia," *Journal of Global Antimicrobial Resistance*, vol. 2, no. 3, pp. 148–154, 2014.
- [6] Z. Breijyeh, B. Jubeh, and R. Karaman, "Resistance of gramnegative bacteria to current antibacterial agents and approaches to resolve it," *Molecules*, vol. 25, no. 6, p. 1340, 2020.
- [7] S. Mamishi, S. Mahmoudi, N. Naserzadeh et al., "Antibiotic resistance and genotyping of gram-negative bacteria causing hospital-acquired infection inpatients referred to Children's Medical Center," *Infection and Drug Resistance*, vol. 12, pp. 3377–3384, 2019.
- [8] A. P. Magiorakos, A. Srinivasan, R. B. Carey et al., "Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance," *Clinical Microbiology and Infection*, vol. 18, no. 3, pp. 268–281, 2012.
- [9] E. Furuya and F. Lowy, "Antimicrobial-resistant bacteria in the community setting," *Nature Reviews. Microbiology*, vol. 4, no. 1, pp. 36–45, 2006.
- [10] H. W. Boucher, G. H. Talbot, J. S. Bradley et al., "Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America," *Clinical Infectious Diseases*, vol. 48, pp. 1–12, 2009.
- [11] WHO, Antimicrobial resistance (WHO fact sheet), WHO, Geneva, 2018, http://www.who.int/en/news-room/factsheets/ detail/antimicrobial-resistance.
- [12] The World Bank, Drug Resistant Infections: A Threat to our Economic Future, The World Bank, Washington D. C, 2017.
- [13] R. C. Founou, L. L. Foulou, and S. Y. Essack, "Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis," *PLoS One*, vol. 12, no. 12, 2017.
- [14] D. M. Livermore and A. Pearson, "Antimicrobial resistance: location, location," *Clinical Microbiology and Infection*, vol. 13, no. 2, pp. 7–16, 2007.
- [15] C. T. Le, *Introductory Biostatistics*, Wiley interscience, Hoboken, New Jersey, US, 2003.
- [16] W. F. S. Badulla, M. Alshakka, and M. I. M. Ibrahim, "Antimicrobial resistance profiles for different isolates in Aden, Yemen: a cross-sectional study in a resource-poor setting," *BioMed Research International*, vol. 2020, Article ID 1810290, 8 pages, 2020.
- [17] D. Muluye, Y. Wondimeneh, G. Ferede, T. Nega, K. Adane, B. Biadgo et al., "Bacterial isolates and their antibiotic susceptibility patterns among patients with pus and/or wound discharge at Gondar university hospital," *BioMedical Central Research Notes*, vol. 7, no. 619, 2014.
- [18] L. Dessalegn, T. Shimelis, E. Tadesse, and S. Gebre-selassie, "Bacterial isolates from post- surgical wound and their antimicrobial susceptibility pattern: a hospital based cross-sectional study," *E3 Journal of Medical Research*, vol. 3, no. 2, pp. 18– 23, 2014.
- [19] Y. Abraham and B. Wamisho, "Microbial susceptibility of bacteria isolated from open fracture wounds presenting to the black-lion hospital, Addis Ababa University," *African Journal* of Microbiology Research, vol. 3, pp. 939–951, 2009.

- [20] M. K. Azene and B. A. Beyene, "Bacteriology and antibiogram of pathogens from wound infections at Dessie Laboratory, North East Ethiopia," *Tanzania Journal of Health Research*, vol. 13, no. 4, pp. 68–78, 2011.
- [21] A. G. Cheng, A. C. DeDent, O. Schneewind, and D. Missiakas, "A play in four acts: Staphylococcus aureus abscess formation," *Trends in Microbiology*, vol. 19, no. 5, pp. 225–232, 2011.
- [22] W. Mulu, B. Abera, M. Yimer, T. Hailu, H. Ayele, and D. Abate, "Bacterial agents and antibiotic resistance profiles of infections from different sites that occurred among patients at Debre Markos Referral Hospital, Ethiopia: a cross-sectional study," *BMC Research Notes*, vol. 10, no. 1, p. 254, 2017.
- [23] T. Alemayehu, M. Ali, E. Mitiku, and M. Hailemariam, "The burden of antimicrobial resistance at tertiary care hospital, southern Ethiopia: a three years' retrospective study," *BMC Infectious Diseases*, vol. 19, no. 1, p. 585, 2019.
- [24] F. B. Solomon, F. W. Wadilo, A. A. Arota, and Y. L. Abraham, "Antibiotic resistant airborne bacteria and their multidrug resistance pattern at University Teaching Referral Hospital in South Ethiopia," *Annals of Clinical Microbiology and Antimicrobials*, vol. 16, no. 1, p. 29, 2017.
- [25] Ethiopian Public Health Institute, *Antimicrobial Resistance Surveillance*, EPHI, Ethiopia, 2018.
- [26] G. Godebo, G. Kibru, and H. Tassew, "Multidrug-resistant bacteria isolates in infected wounds at Jimma University Specialized Hospital, Ethiopia," *Annals of Clinical Microbiology* and Antimicrobials, vol. 12, no. 1, pp. 6-7, 2013.
- [27] C. Stefanak, A. Ieronymaki, T. Matoula et al., "Six-year retrospective review of hospital data on antimicrobial resistance profile of Staphylococcus aureus isolated from skin infections from a single institution in Greece," *Antibiotics*, vol. 6, no. 4, p. 39, 2017.
- [28] D. Alelign, G. Ameya, and M. Siraj, "Bacterial pathogens, drug-resistance profile and its associated factors from patients with suspected peritonitis in Southern Ethiopia," *Infection and Drug Resistance*, vol. 14, pp. 4107–4117, 2021.
- [29] J. G. Damen, S. Faruk, and C. Dancha, "Aerobic bacterial isolates of septic wound infections and their antibiogram in north central Nigeria," *American Journal of Biomedical and Life Sciences*, vol. 3, no. 3, pp. 36–40, 2015.
- [30] A. Melese, C. Genet, and T. Andualem, "Prevalence of vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis," *BMC Infectious Diseases*, vol. 20, no. 1, p. 124, 2020.
- [31] T. Belachew, E. Mulusew, Y. Tolosa, Z. Asefa, H. Negussie, and T. Sori, "Prevalence and antimicrobial-susceptibility profiles of Salmonella in smallhold broiler supply chains in Central Ethiopia," *Infection and Drug Resistance*, vol. 14, pp. 4047–4055, 2021.
- [32] Q. Wang, K. Zhao, C. Guo et al., "Antibiotic resistance and virulence genes of Escherichia coli isolated from patients with urinary tract infections after kidney transplantation from deceased donors," *Infection and Drug Resistance*, vol. 14, pp. 4039–4046, 2021.
- [33] M. Sartelli, D. G. Weber, E. Ruppé et al., "Antimicrobials: a global alliance for optimizing their rational use in intraabdominal infections (AGORA)," *World Journal of Emergency Surgery : WJES*, vol. 11, no. 1, p. 33, 2016.
- [34] M. Imohl and M. V. Linden, "Antimicrobial susceptibility of invasive streptococcus pyogenes Isolates in Germany during 2003-2013," *Journal of Plos ONE*, vol. 10, no. 9, 2015.

- [35] P. Courvalin, "Vancomycin resistance in gram-positive cocci," *Clinical Infectious Diseases*, vol. 42, Supplement_1, pp. S25– S34, 2006.
- [36] M. P. Trish, "The threat of vancomycin resistance," *The American Journal of Medicine*, vol. 106, no. 5, pp. 26–37, 1999.
- [37] K. B. Tuem, A. K. Gebre, T. M. Atey, H. Bitew, E. M. Yimer, and D. F. Berhe, "Drug resistance patterns of Escherichia coli in Ethiopia: a meta-analysis," *BioMed Research International*, vol. 2018, Article ID 4536905, 13 pages, 2018.
- [38] L. Chelkeba, T. Melaku, and T. Ayele, "Gram-negative bacteria isolates and their antibiotic-resistance patterns in patients with wound infection in Ethiopia: a systematic review and metaanalysis," *Infection and Drug Resistance*, vol. 14, pp. 277–302, 2021.
- [39] A. A. Mervat, M. M. Hesham, M. M. Safaa, E. H. Abd, S. El, and M. A. El-Bahnasawy, "Antimicrobial resistance profiles of Enterobacteriaceae isolated from Rosetta Branch of river Nile, Egypt," *World Applied Sciences Journal*, vol. 19, no. 9, pp. 1234–1243, 2012.
- [40] T. Sutherland, C. Mpirimbanyi, E. Nziyomaze et al., "Widespread antimicrobial resistance among bacterial infections in a Rwandan referral hospital," *PLoS One*, vol. 14, no. 8, article e0221121, 2019.
- [41] M. Hailemariam, T. Alemayehu, B. Tadesse et al., "Major bacterial isolate and antibiotic resistance from routine clinical samples in Southern Ethiopia," *Scientific Reports*, vol. 11, no. 1, p. 19710, 2021.
- [42] D. F. Berhe, G. T. Beyene, B. Seyoum et al., "Prevalence of antimicrobial resistance and its clinical implications in Ethiopia: a systematic review," *Antimicrobial Resistance and Infection Control*, vol. 10, no. 1, p. 168, 2021.
- [43] B. O. Motayo, J. I. Ogiogwa, B. W. Aboderin et al., "Bacteriological review of multi-drug resistance (MDR) pathogens involved in respiratory tract infections (RTIS) in Abeokuta, Nigeria," *Journal of Researcher*, vol. 5, pp. 49–55, 2012.
- [44] M. Mama, A. Abdissa, and T. Sewunet, "Antimicrobial susceptibility pattern of bacterial isolates from wound infection and their sensitivity to alternative topical agents at Jimma University Specialized Hospital, South-West Ethiopia," *Journal Annals of Clinical Microbiology and Antimicrobials*, vol. 3, no. 7, p. 1476, 2014.
- [45] W. Mulu, G. Kibru, G. Beyne, and M. Damtie, "Postoperative nosocomial infections and antimicrobial resistance pattern of bacteria isolates among patients admitted at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia," *Ethiopian Journal of Health Sciences*, vol. 22, pp. 1–12, 2012.
- [46] Y. Cag, H. Caskurlu, Y. Fan, B. Cao, and H. Vahaboglu, "Resistance mechanisms," *Annals of Translational Medicine*, vol. 4, no. 17, p. 326, 2016.
- [47] P. S. Lai, L. B. Bebell, C. Meney, L. Valeri, and M. C. White, "Epidemiology of antibiotic-resistant wound infections from six countries in Africa," *BMJ Global Health*, vol. 2, article e000475, Suppl 4, 2018.
- [48] T. B. Tufa, C. R. Mackenzie, H. M. Orth et al., "Prevalence and characterization of antimicrobial resistance among gramnegative bacteria isolated from febrile hospitalized patients in central Ethiopia," *Antimicrobial Resistance and Infection Control*, vol. 11, no. 1, p. 8, 2022.
- [49] T. Alemayehu, "Prevalence of multidrug-resistant bacteria in Ethiopia: a systematic review and meta-analysis," *Journal of Global Antimicrobial Resistance*, vol. 26, pp. 133–139, 2021.

- [50] M. M. Alam, M. N. Islam, M. D. H. Hawlader et al., "Prevalence of multidrug resistance bacterial isolates from infected wound patients in Dhaka, Bangladesh: a cross-sectional study," *International Journal of Surgery Open*, vol. 28, pp. 56–62, 2021.
- [51] A. Sainfer, S. Arlene, and E. Larson, "Prevalence of multidrugresistant gram-negative bacteria among nursing home residents: a systematic review and meta-analysis," *American Journal of Infection Control*, vol. 45, no. 5, pp. 512–518, 2017.
- [52] A. Olowo-Okere, Y. K. E. Ibrahim, L. Z. Nabti, and B. O. Olayinka, "High prevalence of multidrug-resistant Gramnegative bacterial infections in Northwest Nigeria," *Germs*, vol. 10, no. 4, pp. 310–321, 2020.
- [53] T. Ageru Anjulo, H. Seid, T. Sidamo, T. Balcha, and T. L. Abiso, "Antimicrobial resistance profile of clinically isolated bacteria at Wolaita Sodo University Teaching Referral Hospital," *Research Square.*, 2021.